CompletedNot Applicable

Comparison of the Effect of Exercises on Vasomotor Symptoms in Middle Aged Women

Turkey (Türkiye)36 participantsStarted 2023-06-15

Plain-language summary

Vasomotor symptoms (VMS) develop in the premenopausal period and symptoms may persist for years after menopause.Vasomotor symptoms such as hot flashes, night sweats, mood swings and sleep disturbances affect women's quality of life. There is a need for alternative treatments to reduce vasomotor symptoms due to the inadequacy of current treatments and the need for an effective treatment. Exercise is seen as a low-risk treatment to reduce vasomotor symptoms. Resistance trainig combined with aerobic training may be effective in reducing vasomotor symptoms and improving quality of life. The effects of the combination of resistance trainig 2 days a week and aerobic trainig 3 days a week on vasomotor symptoms, quality of life, sleep disturbance and depression will be investigated and compared with the control group.

Who can participate

Age range

40 Years – 65 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Women between the ages of 40-65 * Those who report moderate or severe vasomotor symptoms * Those who have not received hormone replacement therapy for at least 3 months * Maximum of 225 minutes of physical activity per week Exclusion Criteria: * Receiving medical treatment for menopausal symptoms in the past 2 months * Any medical condition or physical inability to participate in exercise training * Systolic blood pressure \>160 mmHg * Diastolic blood pressure \>100 mmHg

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

Change in vasomotor sypmtoms

Timeframe: Baseline (Before intervention) and at the end of the intervention after 12 weeks

Change in the Menopause-specific Quality of Life (MENQOL) Questionnaire

Timeframe: Baseline (Before intervention) and at the end of the intervention after 12 weeks

Change in the Menopause Rating Scale (MRS)

Timeframe: Baseline (Before intervention) and at the end of the intervention after 12 weeks

Trial details

NCT IDNCT05892094

SponsorIstanbul Medipol University Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2024-01-23

View on ClinicalTrials.gov More Hot Flashes trials

Plain-language summary

Who can participate

Age range

40 Years – 65 Years

Sex

FEMALE

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

What they're measuring

Change in vasomotor sypmtoms

Timeframe: Baseline (Before intervention) and at the end of the intervention after 12 weeks

Change in the Menopause-specific Quality of Life (MENQOL) Questionnaire

Timeframe: Baseline (Before intervention) and at the end of the intervention after 12 weeks

Change in the Menopause Rating Scale (MRS)

Timeframe: Baseline (Before intervention) and at the end of the intervention after 12 weeks